Back to top
more

Aphria Inc. (APHA)

(Delayed Data from NYSE)

$6.94 USD

6.94
5,631,062

-0.19 (-2.66%)

Updated May 3, 2019 04:02 PM ET

After-Market: $7.00 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Sanghamitra Saha headshot

5 Top-Ranked Stocks to Tap Earnings Beat Potential

Forget earnings growth, bet on these top-ranked stocks to cash in on earnings beat.

Henry Schein (HSIC) Q1 Earnings and Revenues Top Estimates

Henry Schein (HSIC) sees dismal performance by Dental arm in Q1 due to disruptions resulting from the coronavirus pandemic.

Tandem Diabetes (TNDM) Q1 Loss Widens, Revenues Top Estimates

Tandem Diabetes' (TNDM) strong domestic pump sales and the company's expansion in international markets boost the top line.

What's in the Cards for Quidel (QDEL) This Earnings Season?

Quidel (QDEL) is expected to have gained from its Molecular Diagnostic Solutions business in Q1.

Varian (VAR) Earnings and Revenues Surpass Estimates in Q2

Varian (VAR) continued to gain from core Oncology Systems segment in Q2.

Luminex (LMNX) Q1 Earnings Miss Estimates, Revenues Beat

Luminex's (LMNX) first-quarter earnings benefit from solid performance across Consumable Sales, Assay, Service and Other Revenues.

CONMED (CNMD) Q1 Earnings and Revenues Surpass Estimates

CONMED's (CNMD) first-quarter results gain from strong performance in General Surgery segment and expansion in margins.

Teleflex (TFX) Earnings and Revenues Beat Estimates in Q1

Teleflex's (TFX) first-quarter 2020 results reflect sales growth across few major segments despite the coronavirus pandemic.

Hill-Rom's (HRC) Q2 Earnings Top Estimates, Margins Expand

Hill-Rom (HRC) benefits from increased product demand due to the coronavirus outbreak.

Syneos Health (SYNH) Tops Q1 Earnings Estimates, Margins Down

The coronavirus impact results in inaccessibility of several of Syneos Health's (SYNH) clinical trial sites.

Genetic Testing Likely to Drive Invitae's (NVTA) Q1 Earnings

Invitae's (NVTA) genetic testing business is expected to have gained from expansion of biopharma partnerships in Q1.

PRA Health (PRAH) Q1 Earnings and Revenues Beat Estimates

PRA Health's (PRAH) Clinical Research segment puts up a strong performance in Q1.

What's in the Cards for CVS Health (CVS) in Q1 Earnings?

We expect CVS Health (CVS) to have gained from Aetna's addition of new Individual and Group Medicare Advantage members in Q1.

InMode (INMD) to Post Q1 Earnings: What's in the Offing?

InMode's (INMD) Q1 performance is likely to have been driven by developments in business segments amid coronavirus-led supply disruptions.

What's in the Cards for DaVita (DVA)This Earnings Season?

DaVita (DVA) is expected to have gained from Kidney Care segment in Q1.

What's in Store for Varian Medical (VAR) in Q2 Earnings?

Varian's (VAR) solid Oncology platform is expected to have driven fiscal second-quarter performance.

Illumina (ILMN) Beats Q1 Earnings Estimates, Withdraws View

Illumina (ILMN) exhibits robust growth in the first quarter of 2020 fueled by strong performance of the sequencing consumable subsegment despite the coronavirus pandemic.

ResMed (RMD) Q3 Earnings Top on Higher Ventilator Sales

ResMed's (RMD) adjusted gross margin improves on benefits from changes in product mix, and manufacturing and procurement efficiencies.

Stryker (SYK) Q1 Earnings and Revenues Surpass Estimates

Stryker's (SYK) first-quarter earnings gain from strong performance at MedSurg and Neurotechnology and Spine units.

IDEXX (IDXX) Q1 Earnings Top Estimates, Margins Decline

IDEXX Laboratories (IDXX) companion animal clinical visits decrease due to the impact of the coronavirus pandemic.

Hologic (HOLX) Beats Q2 Earnings Estimates, Withdraws View

Hologic (HOLX) exhibits robust segmental growth in second-quarter fiscal 2020, fueled by strong performance by the Diagnostics segment amid the coronavirus pandemic.

Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates

Surmodics (SRDX) registered growth in one of its core units, Invitro Diagnostics, in Q2.

QIAGEN (QGEN) Q1 Earnings to Gain on Growing Test Kit Sales

QIAGEN (QGEN) is expected to have gained from increased adoption of testing solutions to identify the SARS-CoV-2 in Q1 amid the coronavirus pandemic.

ABIOMED (ABMD) Q4 Earnings Beat Estimates, Revenues Miss

ABIOMED's (ABMD) flagship Impella saw decline in revenues within United States in Q4.

Align Technology (ALGN) Q1 Earnings Miss, Margins Down

Align Technology's (ALGN) Scanner and Services reports COVID-19-led lower sales in North America and APAC region.